Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00905073 · ClinicalTrials.gov registry record · NA

Low Dose Cyclosporin and Methotrexate Therapy in Diabetes

A NA study of Type 1 Diabetes Mellitus, sponsored by Georgetown University.

Completed
Registry status
NA
Development phase
8
Enrollment target
1
Study location

NCT00905073 is a NA study of Type 1 Diabetes Mellitus that has completed, run by Georgetown University. The registered enrollment target is 8 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00905073, a NA study of Type 1 Diabetes Mellitus, has completed, sponsored by Georgetown University.

COMPLETED
Registry status
NA
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether treatment with low dose cyclosporin and methotrexate can inhibit the development of new onset diabetes mellitus

Conditions Studied

Interventions

  • DRUG cyclosporin and methotrexate

Study Locations (1)

District of Columbia

  • Georgetown University - Washington D.C.

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 1990-02
Est. Completion 1994-06
Phase NA

Sponsor

Georgetown University

227 total trials

What the Registry Record Tells You About NCT00905073

The ClinicalTrials.gov registry entry for NCT00905073 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (94% lower). The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which cyclosporin and methotrexate is the first listed.

NCT00905073 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00905073 about?

NCT00905073 is a clinical study titled "Low Dose Cyclosporin and Methotrexate Therapy in Diabetes". The purpose of this study is to determine whether treatment with low dose cyclosporin and methotrexate can inhibit the development of new onset diabetes mellitus

What is the current status of trial NCT00905073?

This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 1990-02. Estimated completion is 1994-06.

What conditions does trial NCT00905073 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.

What interventions are being tested in trial NCT00905073?

The interventions under investigation include: cyclosporin and methotrexate (DRUG).

Who is sponsoring clinical trial NCT00905073?

This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00905073 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.